Gan & Lee Pharmaceuticals Co., Ltd. (603087) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 3.72% and Operating profit at -13.11% over the last 5 years

The company has declared Positive results for the last 8 consecutive quarters

With ROE of 7.85%, it has a expensive valuation with a 3.49 Price to Book Value

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 38,306 Million (Large Cap)

P/E

44.00

Industry P/E

Dividend Yield

2.21%

Debt Equity

-0.19

Return on Equity

7.85%

Price to Book

3.49

Revenue and Profits:

Net Sales:

1,072 Million

(Quarterly Results - Jun 2025)

Net Profit:

292 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-19.49%

6 Months

9.03%

1 Year

34.28%

2 Years

13.21%

3 Years

80.5%

4 Years

-11.17%

5 Years

-43.09%

Gan & Lee Pharmaceuticals Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Gan & Lee Pharmaceuticals Hits Day High with 4.67% Surge in Stock Price

Gan & Lee Pharmaceuticals Co., Ltd. has reported a significant increase in net sales and strong operating cash flow, marking eight consecutive quarters of growth. The company has also benefited from reduced raw material costs, reinforcing its position in the pharmaceuticals and biotechnology sector with a notable market capitalization.

Gan & Lee Pharmaceuticals Hits Day Low of CNY 68.89 Amid Price Pressure

Gan & Lee Pharmaceuticals Co., Ltd. faced a significant stock decline on October 14, 2025, amid a challenging trading session. Despite recent fluctuations, the company has shown strong annual growth and solid financial metrics, including a notable increase in net sales and a favorable market position in the pharmaceuticals sector.

Gan & Lee Pharmaceuticals Hits Day Low Amid Price Pressure at CNY 70.60

Gan & Lee Pharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite recent setbacks, the company has demonstrated strong long-term growth, with notable increases in net sales and operating cash flow, alongside a solid market capitalization and return on equity.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.72%

EBIT Growth (5y)

-13.11%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.21

Sales to Capital Employed (avg)

0.25

Tax Ratio

5.32%

Dividend Payout Ratio

144.23%

Pledged Shares

Institutional Holding

ROCE (avg)

12.46%

ROE (avg)

7.70%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.49

EV to EBIT

52.15

EV to EBITDA

37.27

EV to Capital Employed

4.06

EV to Sales

9.64

PEG Ratio

0.38

Dividend Yield

2.21%

ROCE (Latest)

7.79%

ROE (Latest)

7.85%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 9.89% vs 23.28% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -6.44% vs 190.41% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,072.30",
          "val2": "975.80",
          "chgp": "9.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "354.50",
          "val2": "290.10",
          "chgp": "22.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "18.00",
          "val2": "47.00",
          "chgp": "-61.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "291.80",
          "val2": "311.90",
          "chgp": "-6.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "263.60%",
          "val2": "223.80%",
          "chgp": "3.98%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.66% vs 52.77% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 80.69% vs 177.41% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,014.20",
          "val2": "2,583.80",
          "chgp": "16.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "554.60",
          "val2": "407.10",
          "chgp": "36.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "1.40",
          "chgp": "-64.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "150.90",
          "val2": "-30.50",
          "chgp": "594.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "614.70",
          "val2": "340.20",
          "chgp": "80.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "98.00%",
          "val2": "69.70%",
          "chgp": "2.83%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

1,072.30

975.80

9.89%

Operating Profit (PBDIT) excl Other Income

354.50

290.10

22.20%

Interest

0.00

Exceptional Items

18.00

47.00

-61.70%

Consolidate Net Profit

291.80

311.90

-6.44%

Operating Profit Margin (Excl OI)

263.60%

223.80%

3.98%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 9.89% vs 23.28% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -6.44% vs 190.41% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

3,014.20

2,583.80

16.66%

Operating Profit (PBDIT) excl Other Income

554.60

407.10

36.23%

Interest

0.50

1.40

-64.29%

Exceptional Items

150.90

-30.50

594.75%

Consolidate Net Profit

614.70

340.20

80.69%

Operating Profit Margin (Excl OI)

98.00%

69.70%

2.83%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 16.66% vs 52.77% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 80.69% vs 177.41% in Dec 2023

All Annual Results

Company CV

About Gan & Lee Pharmaceuticals Co., Ltd.

Gan & Lee Pharmaceuticals Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Gan & Lee Pharmaceuticals Co., Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 3.72% and Operating profit at -13.11% over the last 5 years

The company has declared Positive results for the last 8 consecutive quarters

With ROE of 7.85%, it has a expensive valuation with a 3.49 Price to Book Value

Market Beating Performance

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Gan & Lee Pharmaceuticals Hits Day High with 4.67% Surge in Stock Price

Gan & Lee Pharmaceuticals Hits Day Low of CNY 68.89 Amid Price Pressure

Gan & Lee Pharmaceuticals Hits Day Low Amid Price Pressure at CNY 70.60

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Gan & Lee Pharmaceuticals Co., Ltd.

Company Coordinates